KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Financing Activities (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Cash from Financing Activities for 8 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 13.81% year-over-year to $30.2 million, compared with a TTM value of $36.2 million through Dec 2025, down 58.16%, and an annual FY2025 reading of $36.2 million, down 58.16% over the prior year.
  • Cash from Financing Activities was $30.2 million for Q4 2025 at Esperion Therapeutics, up from $10.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $213.4 million in Q4 2021 and bottomed at -$30.4 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $23.7 million, with a median of $4.1 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities skyrocketed 3546.52% in 2023, then crashed 3811.12% in 2024.
  • Year by year, Cash from Financing Activities stood at $213.4 million in 2021, then tumbled by 114.23% to -$30.4 million in 2022, then skyrocketed by 114.73% to $4.5 million in 2023, then soared by 682.73% to $35.0 million in 2024, then dropped by 13.81% to $30.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ESPR at $30.2 million in Q4 2025, $10.7 million in Q3 2025, and $2.8 million in Q2 2025.